Alligator Bioscience AB Interim Report January-March 2018
Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA-4 antibody with tumor-directed properties.” See CEO Per Norlén’s comments on page 2.Significant events January-March 2018• Alligator Bioscience recorded a revenue of USD 6 million from Janssen, coupled to a decision to start combination study with ADC-1013/JNJ-7107.• Theradex Oncology contracted as clinical CRO (Clinical Research Organization) for the upcoming clinical study with ATOR-1015.• Anudharan Balendran appointed VP Business Development